HARMONY FDA Approval NDA 211150

NDA 211150

HARMONY

FDA Drug Application

Application #211150

Documents

Label2019-08-16
Letter2019-08-16
Review2019-09-24
Letter2020-10-14
Label2020-10-14
Label2020-11-03
Letter2020-11-03
Review2021-06-11
Letter2022-12-23
Label2022-12-27

Application Sponsors

NDA 211150HARMONY

Marketing Status

Prescription001
Prescription002

Application Products

001TABLET;ORALEQ 4.45MG BASE1WAKIXPITOLISANT HYDROCHLORIDE
002TABLET;ORALEQ 17.8MG BASE1WAKIXPITOLISANT HYDROCHLORIDE

FDA Submissions

TYPE 1; Type 1 - New Molecular EntityORIG1AP2019-08-14PRIORITY
EFFICACY; EfficacyORIG2AP2020-10-13PRIORITY
LABELING; LabelingSUPPL3AP2022-12-22STANDARD

Submissions Property Types

ORIG1Null2
ORIG2Null2
SUPPL3Null6

CDER Filings

HARMONY
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 211150
            [companyName] => HARMONY
            [docInserts] => ["",""]
            [products] => [{"drugName":"WAKIX","activeIngredients":"PITOLISANT HYDROCHLORIDE","strength":"EQ 4.45MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"No"},{"drugName":"WAKIX","activeIngredients":"PITOLISANT HYDROCHLORIDE","strength":"EQ 17.8MG BASE","dosageForm":"TABLET;ORAL","marketingStatus":"Prescription","te":"None","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"10\/13\/2020","submission":"ORIG-2","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/211150_Orig2s000lbl.pdf\"}]","notes":""},{"actionDate":"08\/14\/2019","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/211150s000lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"10\/13\/2020","submission":"ORIG-2","actionType":"Approval","submissionClassification":"Efficacy","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/211150_Orig2s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2020\\\/211150Orig2s000ltr.pdf\"}]","notes":">"},{"actionDate":"08\/14\/2019","submission":"ORIG-1","actionType":"Approval","submissionClassification":"Type 1 - New Molecular Entity","reviewPriority":"PRIORITY; Orphan","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2019\\\/211150s000lbl.pdf\"},{\"name\":\"Letter (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/appletter\\\/2019\\\/211150Orig1s000ltr.pdf\"},{\"name\":\"Review\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/nda\\\/2019\\\/211150Orig1s000TOC.cfm\"}]","notes":">"}]
            [supplements] => 
            [actionDate] => 2020-10-13
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.